Pre-made Lenvervimab benchmark antibody ( Whole mAb, anti-HBV therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lenvervimab biosimilar, Whole Mab: Anti-HBV therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lenvervimab (INN development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-302-1mg	1mg	3090
GMP-Bios-ab-302-10mg	10mg	Inquiry
GMP-Bios-ab-302-100mg	100mg	Inquiry
GMP-Bios-ab-302-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lenvervimab biosimilar, Whole Mab: Anti-HBV therapeutic antibody
INN Name	Lenvervimab
Target	HBV
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	Green Cross;GC Pharma;AbbVie
Conditions Approved	na
Conditions Active	Hepatitis B
Conditions Discontinued	na
Development Tech	na